Controlled Clinical Trials
DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 16, Number 1, 1995

JANET WITTES
Editorial From the Editor 1

GERRY OSTER, GERALD M. BOROK, JOSEPH MENZIN, JOSEPH F. HEYSE, ROBERT S. EPSTEIN, VIRGINIA QUINN, VICTOR BENSON, R. JAMES DUDL, AND ARNOLD EPSTEIN
A Randomized Trial to Assess Effectiveness and Cost in Clinical Practice: Rationale and Design of the Cholesterol-Reduction Intervention Study (CRIS) 3

MARK S. KAMLET, NANCY PAUL, JOEL GREENHOUSE, DAVID KUPFER, ELLEN FRANK, AND MARTCIA WADE
Cost Utility Analysis of Maintenance Treatment for Recurrent Depression 17

CLARENCE E. DAVIS, WILLIAM B. APPLEGATE, DAVID J. GORDON, R. CAROLYN CURTIS, AND MAUREEN McCORMICK
An Empirical Evaluation of the Placebo Run-in 41

JEFFREY D. HORBAR, KATHLEEN A. LEAHY, FOR THE INVESTIGATORS OF THE VERMONT-OXFORD TRIALS NETWORK
An Assessment of Data Quality in the Vermont-Oxford Trails Network Database 51

DAVID MOHER, ALEJANDRO R. JADAD, GRAHAM NICHOL, MARIE PENMAN, PETER TUGWELL, AND SHARON WALSH
Assessing the Quality of Randomized Controlled Trials: An Annotated Bibliography of Scales and Checklists 62

THE SvO_2 COLLABORATIVE GROUP
The SvO_2 Study: General Design and Results of the Feasibility Phase of a Multicenter, Randomized Trial of Three Different Hemodynamic Approaches and Two Monitoring Techniques in the Treatment of Critically Ill Patients 74

Announcement 88

Volume 16, Number 2, 1995

MYLAN C. COHEN, CAROL McKENNA, STANLEY M. LEWIS, AND JAMES E. MULLER
Requirements for Controlled Clinical Trials of Preoperative Cardiovascular Risk Reduction 89

DAVID M. ZUCKER, EDWARD LAKATOS, LARRY S. WEBBER, DAVID M. MURRAY, SONJA M. McKINLAY, HENRY A. FELDMAN, STEVE H. KELDER, AND PHILIP R. NADER, for the CATCH Study Group
Statistical Design of the Child and Adolescent Trial for Cardiovascular Health (CATCH): Implications of Cluster Randomization 96

PING-YU LIU AND STEVE DAHLBERG
Design and Analysis of Multiarm Clinical Trials with Survival Endpoints 119

JOHAN BRING
Letter to the Editor Stopping a Clinical Trial Early Because of Toxicity: The Bayesian Approach 131

GEORGE W. COMSTOCK
Letter to the Editor Note on Large, Simple, Widely Representative Trials 133

JANET WITTES
List of Reviewers 135

Announcements 136

Volume 16, Number 2, 1995
Supplement
Data Management for Multicenter Studies: Methods and Guidelines

Preface *Barbara S. Hawkins* vii

Contributors viii

Introduction *Ruth McBride and Stephen W. Singer* 1S

Functions and Organization of Coordinating Centers for Multicenter Studies 4S
Brent A. Blumenstein, Kenneth E. James, Bonnie K. Lind, and Herman E. Mitchell

INTRODUCTION 4S
PRIMARY AND SECONDARY MISSIONS 4S
TYPES OF MULTICENTER STUDIES 6S
Single Study in a Single Disease 6S
Multiple Studies of a Single Disease 7S
Multiple Studies and Multiple Diseases 7S
Single Study of Multiple Diseases 8S
RELATIONSHIP OF THE COORDINATING CENTER TO OTHER STUDY COMPONENTS 8S
Field Sites 8S
Resource Centers 11S
Central Laboratories 12S
Expert Interpretation Services 12S
Drug Distribution Services 12S
Intervention Management Services 12S
Scientific Management and Leadership 13S
Study Sponsor 14S
COORDINATING CENTER FUNCTIONS, ORGANIZATION, AND PERSONNEL 15S
Statistical Support 16S
Systems Coordination 19S
Computer Systems Support and Programming 20S
Creation, Acquisition, and Management of Study Materials 23S
Training and Monitoring 24S

Data Operations 25S
Administrative Support 26S
DATA ANALYSIS AND PUBLICATION 26S
DISCUSSION 27S
REFERENCES 28S

Approaches to Data Management 30S
Eleanor T. McFadden, Frances LoPresti, Lance R. Bailey, Ellis Clarke, and Patricia C. Wilkins

INTRODUCTION 30S
REQUIREMENTS ANALYSIS 30S
Objectives 30S
Protocol and Project Scope 31S
Functional Description of Data Interactions 32S
Database Storage Requirements 33S
Validation Criteria 34S
Regulatory Requirements 34S
Staffing and Organizational Constraints 35S
CENTRAL VERSUS DISTRIBUTED DATA PROCESSING 35S
Data Intensity 36S
Data Dispersion 36S
Volatility of Protocol and Data Collection Instruments 36S
Environment of the Coordinating Center and Field Sites 37S
Need for Local Functions 37S
Timeliness Issues 38S
Facsimile Use in the Centralized Model 38S
Computer-Assisted Data Collection in the Distributed Model 38S
Choosing Functions to Be Distributed 39S
Differences in Architecture and Design 40S
Differences in Implementation Schedule 41S
Data Transmission Choices 41S
Choice Among Options 42S
SOFTWARE AND HARDWARE SELECTION 42S
Choosing Database Management Software 42S
Database Types and Models 43S
Relational Model 43S
Hierarchical Model 44S
Other Models 45S
Choice of a Database Model 46S
Operating System 47S
Hardware Selection 48S
DEVELOPMENT, PROJECT MANAGEMENT, AND REPORTING TOOLS 49S
COMMUNICATIONS 49S
Facsimile Transmission 50S
Voice Transmission 50S
Courier and Mail Services 50S
Electronic Data Transfer 50S
Public Telephone System 50S

Public Networks 51S
Electronic Mail 51S
Error Rates and Transmission Integrity 51S
COMPUTER SECURITY 52S
Internal Access 52S
External Access 52S
Malicious Intent 52S
Computer Viruses and Trojan Horses 53S
DATABASE MANAGEMENT SYSTEM ADMINISTRATION 53S
Database Design 54S
Participant Identifier 54S
Key Fields 54S
Data Redundancy 54S
Data Format 54S
Administrative Data 55S
Data Security 55S
Data Integrity and Transaction Processing 55S
Backup and Recovery 56S
Audit Trails 56S
Performance Optimization 57S
CONTROLLING PARTICIPANT ENROLLMENT AND TREATMENT ASSIGNMENT 57S
Telephone Call-in Systems 58S
Envelope Systems 58S
Facsimile or Telecopier Systems 59S
Voice Information Systems 59S
Distributed Systems 60S
Summary of Enrollment and Treatment Assignment Systems 60S
OTHER SOFTWARE DEVELOPMENT OPTIONS 60S
Appointment Schedules 61S
Calendars and Reminders 61S
Local Reports 61S
Data Queries 61S
Auto-Encoding Dictionaries 62S
Inventory Systems 62S
Summary 62S
CONCLUSIONS 62S
REFERENCES 63S

Data Collection and Transcription 66S
James D. Hosking, M. Marvin Newhouse, Anna M. Bagniewska, and Barbara S. Hawkins

INTRODUCTION 66S
DATA COLLECTION 66S
Identifying the Data to Be Collected 66S
Forms Design 67S
Objectives of Forms Design 68S
Standardization of Data Collection Forms 68S
Guidelines for Forms Design 69S
Guidelines for Item Content and Format 70S

Guidelines for Physical Format 71S
Essential Identifying Information for a Form 73S
Guidelines for Identifiers 73S
Item Identifiers 75S
Forms Review and Testing 76S
Forms Production 76S
Organizing Items into Forms 77S
Translating Forms 78S
Review by the Office of Management and Budget 78S
Reproduction and Binding 79S
Producing Copies of Completed Forms 79S
Revisions to Data Collection Forms 80S
Procedures for Data Recording 82S
DATA CODING 84S
When Is Coding Necessary or Desirable? 84S
Recording of Responses Requiring Coding 84S
Who Should Code Information? 86S
When Should Coding Take Place? 88S
Level of Detail Required When Coding 88S
Standard Coding Dictionaries 90S
Guidelines for Developing Special Purpose Codes 90S
DATA ENTRY METHODS AND TOOLS 91S
Introduction 91S
Organization of Data Entry 91S
Desirable Functions and Capabilities of Data Entry Systems 91S
Display and Flow Capabilities 91S
Data Edits During Entry 93S
Missing or Special Value Codes 97S
Rekey Verification 97S
Error Rates 98S
Corrections 99S
Interface to Other Software 99S
Alternatives to Key Entry 100S
REFERENCES 101S

Data Quality Assurance, Monitoring, and Reporting 104S
Jennifer J. Gassman, Walter W. Owen, Timothy E. Kuntz, Jeffrey P. Martin, and William P. Amoroso

INTRODUCTION 104S
ROUTINE AUTOMATED EDITS 109S
Guiding Principles 109S
Selection of Data for Checking 110S
Types of Data Element Checks 110S
Routine Data Edits at the Key Entry Level 112S
Routine Data Edits at the Central Database Level 112S
Checks on Database Quality During Data Analysis and Reporting 114S
Handling Anomalous Data 114S

RESOLVING DISCREPANCIES: DATA QUERIES AND RESPONSES 115S
Content of Data Queries 115S
Communicating with Field Sites About Data Anomalies 117S
Field Site Responses to Queries 117S
Correction of the Database 118S
Tracking Corrections and Other Changes to the Database 120S
MONITORING ACCURACY, CURRENCY, AND INTEGRITY OF THE DATABASE 120S
Monitoring Completeness and Currency of the Database 120S
Monitoring Timeliness of Data Submission 121S
Monitoring Accuracy of Data Collection 121S
Monitoring Accuracy of Data Entry 122S
Monitoring Accuracy of Data Transmission 123S
Monitoring Quality of the Data Management System 123S
Monitoring Delays in Responses to Queries 124S
DATA QUALITY REPORTS 125S
Discrepancies and Error Corrections 125S
Accuracy, Currency, and Completeness of the Study Database 125S
Resource Center Quality Monitoring and Performance Reports 126S
Coordinating Center Quality Monitoring and Reports 127S
PROMOTION OF TIMELY AND ACCURATE DATA COLLECTION AND REPORTING 128S
Training and Certification 128S
Field Site Management Aids and Reminders 129S
Considerations for Design and Production 129S
Scheduling Aids 130S
Missing Materials Reminders 131S
Other Aids 131S
Site Visits and Record Audits 131S
Visits to Field Sites 131S
Site Visits to Resource Centers 132S
Site Visits to the Coordinating Center 133S
SUMMARY AND CONCLUSIONS 133S
REFERENCES 134S

Interim Reports, Participant Closeout, and Study Archives 137S
Ruth McBride and Stephen W. Singer

INTRODUCTION 137S
INTERIM REPORTS 137S
Performance Monitoring Reports 138S
Treatment Effects Monitoring Reports 141S

General Considerations for Design of Reports 143S
Production of Reports 148S
Selecting the Dataset 149S
Preparations for a Database Freeze 151S
Creating the Interim Analysis Dataset 151S
Generating the Contents: Reporting Tools and Software 153S
Checking the Report 154S
PARTICIPANT CLOSEOUT 155S
Collection of Additional Information at Participant Closeout Contacts 155S
Final Validation, Correction, and Closure of the Study Database 157S
Issues Related to Early Termination of a Clinical Trial 158S
Dissemination of Study Findings 160S
STUDY ARCHIVES 161S
Archives Established and Maintained During Study Execution 163S
Archives Established at Study Completion 163S
CONCLUSION 165S
REFERENCES 166S

Appendix A: Glossary 168S

Appendix B: Studies Cited and Sources of Information 175S

Appendix C: Reviewers for This Issue 179S

Volume 16, Number 3, 1995

GENELL L. KNATTERUD AND CURTIS L. MEINERT
A Tribute to Christian Robert Klimt 139

NOWAMAGBE A. OMOIGUI AND ERIC J. TOPOL
Observational versus Randomized Medical Device Testing Before and After Market Approval—The Atherectomy-verus-Angioplasty Controversy 143

POLLY FEIGL, BRENT BLUMENSTEIN, IAN THOMPSON, JOHN CROWLEY, MICHAEL WOLF, BARNETT S. KRAMER, CHARLES A. COLTMAN, JR., OTIS W. BRAWLEY, AND LESLIE G. FORD
Design of the Prostate Cancer Prevention Trial (PCPT) 150

SUNG C. CHOI, TERESA P. GERMANSON, AND THOMAS Y. BARNES
A Simple Measure in Defining Optimal Strata in Clinical Trials 164

PETER FAYERS, DELLA GIBSON, AND JEAN MOSSMAN
UKCCCR Register of U.K. Cancer Trials 172

HORST J. KOCH
Letter to the Editor 182

WILLIAM M. VOLLMER, MOLLY L. OSBORNE, STEPHANIE HERTERT, AND A. SONIA BUIST
In Response to Dr. Koch's Letter 184

Books Received 185

Announcement 186

Volume 16, Number 3, 1995
Supplement

Letter from the President 1S
Calendar of Program 3S
Abstracts: Sixteenth Annual Meeting of the Society of Clinical Trials 33S
Author Index 142S

Volume 16, Number 4, 1995

Workshop on "David Byar: An Accidental Career"

David P. Byar, MD 187
SYLVAN B. GREEN
David Byar: An Accidental Career 189
SAMUEL W. GREENHOUSE
Dave Byar as a Student 191
MARVIN A. SCHNEIDERMAN
David Byar as a Supervisee 193
NATHAN MANTEL
David Byar as a Collaborator 197
STEVEN PIANTADOSI
David Byar as a Teacher 202
Edited Composite of Floor Discussions Following Presentations by S. Greenhouse, M. Schneiderman, N. Mantel, and S. Piantadosi 212
LINCOLN E. MOSES
Some of David Byar's Work: In Appreciation 216
MITCHELL H. GAIL
Dave Byar's Contribution to Epidemiology 230
ROSS L. PRENTICE
On the Role, Design, and Analysis of Disease Prevention Trials 249
PETER ARMITAGE
David Byar's Approach to the Analysis of Survival Data with Covariates 259
MARK HARRINGTON
In Memoriam: David Byar as an AIDS Activist 270

Volume 16, Number 4, 1995
Supplement
The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial

Contributors viii
TRUDY L. BUSH, MARK A. ESPELAND, AND IRMA MEBANE-SIMS
Overview 1S
MARK A. ESPELAND, TRUDY L. BUSH, IRMA MEBANE-SIMS, MARCIA L. STEFANICK, SUSAN JOHNSON, ROGER SHERWIN, AND MYRON WACLAWIW
Rationale, Design, and Conduct of the PEPI Trial 3S

SUSAN JOHNSON, IRMA MEBANE-SIMS, PATRICIA E. HOGAN, AND DIANE B. STOY
Recruitment of Postmenopausal Women in the PEPI Trial 20S

PETER D. WOOD, GERALD KESSLER, KENNETH LIPPEL, MARCIA L. STEFANICK, CAROL H. WASILAUSKAS, AND H. BRADLEY WELLS
Physical and Laboratory Measurements in the PEPI Trial 36S

VALERY T. MILLER, ROBERT L. BYINGTON, MARK A. ESPELAND, ROBERT LANGER, ROBERT MARCUS, SALLY SHUMAKER, AND MICHAEL P. STERN
Baseline Characteristics of the PEPI Participants 54S

References 66S

Appendix I: Key Clinic Personnel 73S

Appendix II: Sample Consent Form 76S

Volume 16, Number 5, 1995

LAURENCE S. FREEDMAN, RICHARD SIMON, MARY A. FOULKES, LAWRENCE FRIEDMAN, NANCY L. GELLER, DAVID J. GORDON, AND RICHARD MOWERY
Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists 277

JEAN-PIERRE BOISSEL, FRANÇOIS GUEYFFIER, AND MARGARET HAUGH
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists" 286

MARTIAL G. BOURASSA
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists" 289

SHEILA M. GORE
Inclusion of Women and Minorities in Clinical Trials 290

OTIS W. BRAWLEY
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists" 293

A. SONIA BUIST AND MERWYN R. GREENLICK
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists" 296

WILLIAM D. FRASER
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists" 299

WENDY BALDWIN
Impact of the NIH Inclusion Guidelines 300

ROBERT F. WOOLSON, MARTHA F. JONES, WILLIAM R. CLARKE, AND JAMES C. TORNER
Discussion of "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists" 301

CURTIS L. MEINERT
Comments of NIH Clinical Trials Valid Analysis Requirement 304

STEVEN PLANTADOSI
Commentary Regarding "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists" 307

LAURENCE S. FREEDMAN, RICHARD SIMON, MARY A. FOULKES, LAWRENCE FRIEDMAN, NANCY L. GELLER, DAVID J. GORDON, AND RICHARD MOWERY
Response to Discussants' Letters 310

JOSEPH B. KADANE
Prime Time for Bayes 313

JEAN-PIERRE BOISSEL, ISABELLE DURIEU, PASCAL GIRARD, PATRICE NONY, FRANCK CHAUVIN, AND MARGARET HAUGH
Dose-Ranging Trials: Guidelines for Data Collection and Standardized Descriptions 319

WILLIAM G. HENDERSON, THOMAS MORITZ, STEVEN GOLDMAN, JACK COPELAND, AND GULSHAN SETHI
Use of Cumulative Meta-Analysis in the Design, Monitoring, and Final Analysis of a Clinical Trial: A Case Study 331

MIRIAM C. CHERNOFF, MINGZHU WANG, JENNIFER J. ANDERSON, AND DAVID T. FELSON
Problems and Suggested Solutions in Creating an Archive of Clinical Trials Data to Permit Later Meta-Analysis: An Example of Methotrexate Trials in Rheumatoid Arthritis 342

TIE-HUA NG
Conventional Null Hypothesis Testing in Active Control Equivalence Studies 356

TOSIYA SATO
Letter to the Editor 359

Volume 16, Number 6, 1995

STEPHEN W. SINGER AND CURTIS L. MEINERT
Format-Independent Data Collection Forms 363

NEIL R. POWE AND ROBERT I. GRIFFITHS
The Clinical-Economic Trial: Promise, Problems, and Challenges 377

JOANNA H. SHIH
Sample Size Calculation for Complex Clinical Trials with Survival Endpoints 395

DAVID L. DEMETS, THOMAS R. FLEMING, RICHARD J. WHITLEY, JAMES F. CHILDRESS, SUSAN S. ELLENBERG, MARY FOULKES, KENNETH H. MAYER, JUDITH O'FALLON, RICHARD B. POLLARD, JAMES J. RAHAL, MERLE SANDE, STEPHEN STRAUS, LEROY WALTERS, AND PATRICIA WHITLEY-WILLIAMS
The Data and Safety Monitoring Board and Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials 408

TERENCE A. GERACE, VALERIE ANNE GEORGE, AND ISABEL G. ARANGO
Response Rates to Six Recruitment Mailing Formats and Two Messages about a Nutrition Program for Women 50–79 Years Old 422

SAMUEL CHARACHE, MICHAEL L. TERRIN, RICHARD D. MOORE, GEORGE J. DOVER, ROBERT P. MCMAHON, FRANCA B. BARTON, MYRON WACLAWIW, SUSAN ECKERT, AND INVESTIGATORS OF THE MULTICENTER STUDY OF HYDROXYUREA
Design of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia 432

MICHAEL T. STEVENS AND THOMAS J. URYNIAK
Response to S.J. Day Letter 447

JAMES ROCHON
Letter to the Editor: Sample Size Calculations for Repeated Measures Experiments 449

JOHN E. OVERALL AND SUZANNE R. DOYLE
Letter to the Editor: Comment on the Substitution of z for t and on Hotelling's T^2 for Repeated Measurements 451

BRENT A. BLUMENSTEIN
Letter to the Editor: Medical Research Data 453

DELLA GIBSON, ANGELA J. HARVEY, AND MAHESH K.B. PARMAR
Letter to the Editor: Response to Dr. Blumenstein's Letter 455

WILLIAM R. FAIRWEATHER
Book Review: *Drug Safety Assessment in Clinical Trials* 456

BARBARA S. HAWKINS
Book Review: *Clinical Data Management* 458

Volume 16 Author Index 460

Volume 16 Subject Index 462

Volume Contents